{"name":"Morphotek","slug":"morphotek","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Chemo Plus Far","genericName":"Chemo Plus Far","slug":"chemo-plus-far","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Chemo Plus Far","genericName":"Chemo Plus Far","slug":"chemo-plus-far","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPWWVGWUlQcktWVFRXb0RmSG5BZkpZblVlckRJVkRsOHhsSnBXNDBQVWotWFpXSUwzajJzOUkwN2NLc05EUHFad3BHeDVsbXd3Si02b0ZPS1BvZVBDUDIzQ3l1aENZS1hKSGh4RjJfb1dfMXo1aFNuNGFfR0ZaSmV3WHk0eWpOT290VTlPVVJHRHNqRkZ0ZjQ2bndodUhfZVZMLUVyTnJwZ2FjNUxrbEZFUDV2c3gxVE9NQ1NXTi04OTJHR1AxT0xzYU1wanNhTnNKQnpWbTB4SWdITXVxcEdJUW5qcDVqYjBxUU5BSl9zNmplYTRPdlRj?oc=5","date":"2016-10-03","type":"pipeline","source":"PR Newswire","summary":"Morphotek and Eurofarma Laboratórios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America - PR Newswire","headline":"Morphotek and Eurofarma Laboratórios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxQcWRGQzFnVnlCQUJhaHh1Wm9CTC1GY2hPem4xU0tkU205VUVrTHJsOTZMSi1yVFdJYl85N1ZFVVBSZVFsVlRBM2RlSXZPSnFmSkFOeHNkUGNyLXRlYTExYTQzQk1ObHA5dC0tZDdVeGkwdVZDN0d6cnRjVTc5WW9LME9NYWZGZ2pYa0h4WWFHSzI3M0tvUUFfYVlTX0NlTmlBbzFGSDdNbHBfQmtIT3VYMkl5c196YXVWWjdILTZ5aWwyS2RsTFlJMHlmUklVcS1JODVhUVhwZzBNSkNvZXFGSkUyRERVekEtQ3pjbnFYTjFaejhiWEYzRnF3N19xdWZpMG5nOXlUZnhoN3B2RWJB?oc=5","date":"2015-11-09","type":"deal","source":"PR Newswire","summary":"Morphotek®, Inc. Announces A License Agreement With Blaze Bioscience, Inc. For The Development Of Novel Oncology Imaging Technology - PR Newswire","headline":"Morphotek®, Inc. Announces A License Agreement With Blaze Bioscience, Inc. For The Development Of Novel Oncology Imaging","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}